Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

https://www.news-medical.net/news/20260928/Continuous-glucose-monitors-show-strong-survival-benefits-for-type-2-diabetes-patients.aspx People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2). The findings provide the first evidence of an association between advanced CGM technologies and lower risk of death in people living with T2D receiving therapy with basal insulin with or without noninsulin diabetes medications, and also show a reduced risk of cardiovascular events, say researchers.